Home LiteratureArticle Details
PMID: 20516428 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Immune regulation of cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology ·Vol. 28 ·No. 29 ·2010-10-10 ·Pages 4531-8

Disis ML

Abstract

Innate and adaptive immune system cells play a major role in regulating the growth of cancer. Although it is commonly thought that an immune response localized to the tumor will inhibit cancer growth, it is clear that some types of inflammation induced in a tumor may also lead to cancer proliferation, invasion, and dissemination. Recent evidence suggests, however, that some patients with cancer can mount an antitumor immune response that has the potential to control or eliminate cancer. Indeed, a so-called "immune response" signature has been described in malignancy that is associated with improved outcomes in several tumor types. Moreover, the presence of specific subsets of T cells, which have the capability to penetrate tumor stroma and infiltrate deep into the parenchyma, identifies patients with an improved prognosis. Immune-based therapies have the potential to modulate the tumor microenvironment by eliciting immune system cells that will initiate acute inflammation that leads to tissue destruction.

MeSH Terms
Adaptive Immunity/immunology Cytokines/immunology,metabolism Dendritic Cells/immunology,metabolism Humans Immunity, Innate/immunology Immunotherapy/methods Models, Immunological Neoplasms/immunology,metabolism,therapy T-Lymphocytes, Cytotoxic/metabolism T-Lymphocytes, Helper-Inducer/immunology,metabolism
Chemicals
Cytokines
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Disis Mary L
Center for Translational Medicine in Women's Health, University of Washington, Seattle, WA 98109, USA. ndisis@u.washington.edu
References (72)
72 references, click to expand
  1. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer.
    Clin Cancer Res. 2009 Jan 1;15(1):284-90 PMID: 19118056
  2. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.
    Crit Rev Oncol Hematol. 2008 Apr;66(1):1-9 PMID: 17913510
  3. Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.
    Genome Biol. 2007;8(1):R8 PMID: 17222352
  4. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10.
    Immunity. 2008 Apr;28(4):468-76 PMID: 18400189
  5. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  6. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
    Blood. 2008 Aug 1;112(3):610-8 PMID: 18519811
  7. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma.
    J Clin Oncol. 2008 Jun 1;26(16):2707-16 PMID: 18509183
  8. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  9. The sound of silence: modulating anergy in T lymphocytes.
    Curr Opin Immunol. 2007 Dec;19(6):658-64 PMID: 17949964
  10. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.
    J Immunol. 2007 Jul 15;179(2):977-83 PMID: 17617589
  11. Polarized immune responses differentially regulate cancer development.
    Immunol Rev. 2008 Apr;222:145-54 PMID: 18363999
  12. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.
    J Clin Oncol. 2008 Sep 20;26(27):4410-7 PMID: 18802153
  13. Prognostic significance of autoimmunity during treatment of melanoma with interferon.
    N Engl J Med. 2006 Feb 16;354(7):709-18 PMID: 16481638
  14. IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host.
    J Immunol. 2009 Jul 1;183(1):51-8 PMID: 19535638
  15. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.
    Nat Med. 2000 Apr;6(4):443-6 PMID: 10742152
  16. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.
    Cancer Cell. 2005 May;7(5):411-23 PMID: 15894262
  17. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
    Science. 2002 Oct 25;298(5594):850-4 PMID: 12242449
  18. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
    J Clin Oncol. 2005 Apr 1;23(10):2346-57 PMID: 15800326
  19. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
    J Clin Oncol. 2006 Jul 1;24(19):3089-94 PMID: 16809734
  20. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.
    J Immunol. 2009 May 1;182(9):5240-9 PMID: 19380770
  21. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer.
    Am J Respir Crit Care Med. 2008 Apr 1;177(7):763-70 PMID: 18096709
  22. Friendly and dangerous signals: is the tissue in control?
    Nat Immunol. 2007 Jan;8(1):11-3 PMID: 17179963
  23. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.
    Clin Cancer Res. 2009 Feb 1;15(3):971-9 PMID: 19188168
  24. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
    J Clin Oncol. 2009 Jan 10;27(2):186-92 PMID: 19064967
  25. CD4 regulatory T cells in human cancer pathogenesis.
    Cancer Immunol Immunother. 2007 Mar;56(3):271-85 PMID: 16819631
  26. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    N Engl J Med. 2007 May 10;356(19):1928-43 PMID: 17494926
  27. Inflammation: a driving force speeds cancer metastasis.
    Cell Cycle. 2009 Oct 15;8(20):3267-73 PMID: 19770594
  28. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
    N Engl J Med. 2003 Jan 16;348(3):203-13 PMID: 12529460
  29. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.
    Cancer Cell. 2009 Aug 4;16(2):91-102 PMID: 19647220
  30. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.
    Science. 2006 Sep 29;313(5795):1960-4 PMID: 17008531
  31. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.
    J Clin Oncol. 2006 Dec 1;24(34):5373-80 PMID: 17135638
  32. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma.
    Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):3967-72 PMID: 17360461
  33. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.
    N Engl J Med. 2009 Nov 5;361(19):1838-47 PMID: 19890126
  34. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?
    Immunity. 2009 May;30(5):626-35 PMID: 19464985
  35. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
    J Clin Oncol. 1996 Jan;14(1):7-17 PMID: 8558223
  36. Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients.
    PLoS One. 2009 Oct 02;4(10):e7234 PMID: 19798410
  37. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
    J Clin Oncol. 2009 Oct 1;27(28):4685-92 PMID: 19720923
  38. Analysis of breast cancer related gene expression using natural splines and the Cox proportional hazard model to identify prognostic associations.
    Breast Cancer Res Treat. 2010 Aug;122(3):711-20 PMID: 19859804
  39. Myeloid-derived suppressor cells as regulators of the immune system.
    Nat Rev Immunol. 2009 Mar;9(3):162-74 PMID: 19197294
  40. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
    J Clin Invest. 2005 Dec;115(12):3623-33 PMID: 16308572
  41. Interferons, immunity and cancer immunoediting.
    Nat Rev Immunol. 2006 Nov;6(11):836-48 PMID: 17063185
  42. Biologic predictors in follicular lymphoma: importance of markers of immune response.
    Leuk Lymphoma. 2007 Dec;48(12):2403-11 PMID: 18067016
  43. The current status of intravesical therapy for superficial bladder cancer.
    Curr Opin Urol. 2003 Sep;13(5):357-62 PMID: 12917511
  44. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.
    Clin Cancer Res. 2009 Sep 1;15(17):5323-37 PMID: 19723653
  45. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
    J Clin Oncol. 2007 Jun 20;25(18):2586-93 PMID: 17577038
  46. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.
    Cancer. 2006 Dec 15;107(12):2866-72 PMID: 17099880
  47. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
    J Clin Oncol. 2009 Feb 20;27(6):945-52 PMID: 19139436
  48. Macrophage polarization in tumour progression.
    Semin Cancer Biol. 2008 Oct;18(5):349-55 PMID: 18467122
  49. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers.
    Clin Cancer Res. 2006 Jan 15;12(2):465-72 PMID: 16428488
  50. The Janus face of dendritic cells in cancer.
    Oncogene. 2008 Oct 6;27(45):5920-31 PMID: 18836473
  51. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
    J Clin Oncol. 2005 Sep 1;23(25):6043-53 PMID: 16087944
  52. A controlled trial of a human papillomavirus type 16 vaccine.
    N Engl J Med. 2002 Nov 21;347(21):1645-51 PMID: 12444178
  53. Effector memory T cells, early metastasis, and survival in colorectal cancer.
    N Engl J Med. 2005 Dec 22;353(25):2654-66 PMID: 16371631
  54. Cancer-related inflammation.
    Nature. 2008 Jul 24;454(7203):436-44 PMID: 18650914
  55. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity.
    Eur J Immunol. 2009 Aug;39(8):2076-82 PMID: 19672903
  56. Myeloid-derived suppressor cells: linking inflammation and cancer.
    J Immunol. 2009 Apr 15;182(8):4499-506 PMID: 19342621
  57. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.
    Blood. 2006 Nov 1;108(9):2957-64 PMID: 16825494
  58. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Expert Rev Vaccines. 2007 Jun;6(3):307-17 PMID: 17542746
  59. Enhancing cancer vaccine efficacy via modulation of the tumor microenvironment.
    Clin Cancer Res. 2009 Nov 1;15(21):6476-8 PMID: 19861446
  60. Evidence for immune defects in breast and lung cancer patients.
    Cancer Immunol Immunother. 2004 Dec;53(12):1146-52 PMID: 15185014
  61. Mechanism of action and other potential roles of an immune response modifier.
    Cutis. 2007 Apr;79(4 Suppl):36-45 PMID: 17508494
  62. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
    Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5 PMID: 17360651
  63. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
    Nat Med. 1999 Oct;5(10):1171-7 PMID: 10502821
  64. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells.
    J Exp Med. 2009 Aug 3;206(8):1755-67 PMID: 19635862
  65. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
    Blood. 1990 Dec 15;76(12):2462-5 PMID: 2265242
  66. A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder.
    Urol Oncol. 2011 Jan-Feb;29(1):58-65 PMID: 19837616
  67. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection.
    Transpl Int. 2009 Mar;22(3):293-302 PMID: 19017305
  68. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
    J Exp Med. 2002 Sep 2;196(5):619-28 PMID: 12208877
  69. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity.
    Mol Cancer Ther. 2008 Mar;7(3):449-54 PMID: 18319334
  70. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
    J Natl Cancer Inst. 2009 Jun 16;101(12):869-77 PMID: 19509353
  71. Cancer vaccines: between the idea and the reality.
    Nat Rev Immunol. 2003 Aug;3(8):630-41 PMID: 12974478
  72. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
    Cancer. 1996 Apr 1;77(7):1303-10 PMID: 8608507
Article Info
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Abbr.
J Clin Oncol
ISSN
1527-7755
DOI
10.1200/JCO.2009.27.2146
Email
ndisis@u.washington.edu
Published
2010-10-10
Epub
2010-00-01
Pages
4531-8
Language
English
Region
United States
NLM ID
8309333
PMCID
PMC3041789
Subset
IM
Grants
NCI NIH HHS · CA101190 · United States
NCI NIH HHS · R01 CA129517 · United States
NCI NIH HHS · CA 129517 · United States
NCI NIH HHS · R01 CA101190 · United States
NCI NIH HHS · R01 CA098761 · United States
External Links
PubMed source DOI: 10.1200/JCO.2009.27.2146 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2